Antimicrobials
Clindamycin

Clindamycin

High
Excellent

Dosing

General Information

Primary

  • For use in combination for treatment of Group A streptococcus (Streptococcus pyogenes) or Staphylococcus aureus infections causing toxic shock syndrome or necrotizing fasciitis

Alternative

  • Noninvasive MRSA infections, if susceptible, without alternative option such as TMP/SMX or doxycycline
  • Part of combination therapy for Pneumocystis, Toxoplasma

Is metabolized predominantly by CYP3A4. Inhibitors of CYP3A4 may reduce clearance and inducers may increase clearance.

Stool frequency

GASTROINTESTINAL

  • Diarrhea may be severe and persistent
  • C. difficile colitis may occur up to several weeks post therapy.

DERMATOLOGICAL

  • Thrombophlebitis
  • Generalised mild to moderate morbillium-like rash

MISCELLANEOUS

  • Bad or bitter taste in mouth
  • Anaphylactoid reactions (rare)
  • Cardiopulmonary arrest and hypotension following administration at rates faster than 30 mg/min (case reports)

Can be given via deep IM injection

Subcutaneous: no information available at this time

Antimicrobial class: Lincosamide (Antibiotic)

Pregnancy category: B

Average serum half life: 2.4 hours

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Poor

Biliary penetration: Therapeutic